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The main purpose of this theoretical and practical workshop
is to clearly deﬁne why and how to deﬁne volumes such as
gross tumour volume (GTV), clinical tumour volume (CTV) and
organs at risk (OAR) for use in intensity modulated radiothe-
rapy (IMRT), as well as in for computed tomography (CT) and
magnetic resonance imaging (MRI)-based brachytherapy (BT)
for the exclusive and post-operative approach of cervical can-
cer. The workshop consists of two parts; the ﬁrst is theoretical
and the second will be developed in two practice groups: one
for volume deﬁnition in brachytherapy and the other for IMRT.
Finally, we will close the workshop with the take home con-
clusions.
Until recently, gynaecologic cancer treatment planning in
many centres was only based on two-dimensional (2D) X-ray
images to perform external radiotherapy and BT treatments.
When moving from 2D- to 3D-based treatment planning in
clinical routine, it is necessary to consider three major top-
ics in each modality: volume deﬁnition, volume parameters,
radiobiological concepts, and ﬁnally the integration of the two.
Quantitative radiobiologicalmodelling is highly useful to com-
pare treatment regimens, to design a personalised strategy
and to analyse clinical trials.
Most radiation oncologists routinely use dose–volume
histograms, with the input from radiobiological modelling
allowing their interpretation. The utility of other tools such as
equivalent uniform dose, tumour control probability, normal
tissue complication probability and uncomplicated tumour
control probability will be discussed with clinical examples
in this workshop.
Nowadays, a properly implemented IMRT treatment
(which implies good imaging, delineation of volumes, careful
planning and treatment delivery) can offer adequate GTV cov-
erage with a reduction of dose in OAR. Several retrospective
studies have reported positive results in local control and sur-
vival and a reduction of dose in OAR with clinical impact. As a
result, the 0418 RTOG trial is currently analysing this topic and
has found a reduction in early G2 gastrointestinal (GI) toxicity.
Nevertheless, despite the reduction in late GI complications,
the follow-up of the patients does not at present, allow sig-
niﬁcant results. The INTERTEC multicentric international trial
is now analysing the reproductibility of GTV and OAR delin-
eation between different centres as well as the results of IMRT
in the exclusive treatment setting of cervical cancer. Until the
results of these studies are available some guidelines by the
RTOG describe how to perform volume delineation in IMRT in
the treatment of cervical cancer patients.
Several studies have shown beneﬁts in local control, sur-
vival and complications when MRI-guided BT is performed
after external beam irradiation. The results have led the GEC-
ESTRO to set out some clear recommendations to delimit
gynaecological BT volumes by MRI. These GEC-ESTRO recom-
mendations deﬁne several volumes of different risk of disease
for prescription of the dose at the time of BT and at diagno-
sis, always based on the image parameters (MRI) and physical
examination. They deﬁne:
Gross tumour volume (GTV) as the macroscopic residual
tumor at BT and visualized on T2-MRI (high signal intensity
mass).
High-risk CTV (HR CTV): the area of major risk of local recur-
rence because of residualmacroscopic disease. This includes
the GTV, the whole cervix and the presumed extracervical
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tumour extension at the time of BT (clinical examination
and MRI ﬁndings). HR CTV includes palpable indurations
and/or residual grey zones in the parametrium, uterine cor-
pus, vagina and organs at risk without margins.
Intermediate CTV (IR-CTV): the area of mayor risk of
local recurrence because of microscopic disease. This also
includesHR-CTVwith amargin of 5–15mmchosenaccording
to tumour size, location, potential tumour spread, response
to external radiotherapy and treatment strategy.
Organs at risk: rectum, bladder and sigmoid. The outer con-
tour of OAR must be drawn to limit the dose to 2 cc (DV2cc,
DR2cc, and DS2cc).
When using CT, the GTV cannot be distinguished, therefore
only a CTV or target can be drawn that includes the cervix, the
lower part of the uterus and upper vagina, but the parame-
trial extension cannot be deﬁned. If parametrial involvement
is present, interstitial BT using plastic needles adapted to
the colpostats/ring applicator or MUPIT is useful, and MRI is
mandatory.
The dose in cervix BT traditionally was prescribed to
anatomic points (points A or B) or reference isodoses (60Gy)
considering the tolerance dose in rectum and bladder based
on ICRU points. After the GEC-ESTRO recommendations the
dose should be prescribed to ensure that the tumour and the
cervix are encompassed; nonetheless, the dose to the classi-
cal reference points A–H should also be taken into account.
Two consensus of the Spanish BT Group have described the
rules to draw contours for cervical and endometrial carci-
noma. At present, a new ICRU report is currently in progress
on “Dose and volume reporting in brachytherapy in cervical
cancer”.
The “new-tech” for cervical cancer treatment seems tooffer
solutions for the considered “old problem in cancer treat-
ment”, that is the continuous war to increase local control
and survival with a reduction of treatment-related toxicity.
Nevertheless, this “new-tech” is not equitatively available in
all the hospitals and thus the “old problem” albeit reduced,
continues.
